Molecular Partners AG (NASDAQ:MOLN) and its partner Novartis AG (NYSE:NVS), have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.
- This submission is based on the totality of the data from clinical and preclinical studies, including the results of the Phase 2 portion of the EMPATHY study, which enrolled 407 symptomatic COVID-19 patients.
- Related: Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data.
- Ensovibep is a DARPin therapeutic candidate designed specifically to inhibit target cell entry of SARS-CoV-2, the virus that causes COVID-19.
- DARPin's (Designed Ankyrin Repeat Proteins) are mono or multi-specific protein-based therapies designed to engage their targets for various effects specifically. E
- Price Action: MOLN shares traded 0.27% higher at $26.19, NVS shares are up 0.72% at $87.83 during the premarket session on the last check Thursday.
